AVXL news

Anavex completed clinical conduct for DDI and ADME studies of blarcamesine, aiding the Alzheimer's pipeline; FDA cleared an IND for Fragile X syndrome. These developments reflect strong clinical advancement and execution.

Anavex Life Sciences has filed its quarterly reports for Q2 and Q3 2026, bringing the company back into full compliance with Nasdaq listing standards pending the ticker's reinstatement.

Anavex Life Sciences reported financial results for Q3 2026 and submitted completed AD clinical data to the FDA, with upcoming IND submissions for Rett Syndrome and Fragile X Syndrome.

Anavex Life Sciences nominated two new independent directors and filed a preliminary proxy statement to reject takeover attempts by PVG Asset Management and Patrick Adams while establishing an Executive Committee led by Dr. Jiong Ma.

Anavex Life Sciences filed an IND for ANAVEX2-73 targeting early Alzheimer's disease. The company implemented a disciplined data-driven strategy focusing on FDA engagement.

Anavex Life Sciences received a delinquency notification from Nasdaq on May 20, 2026, due to failure to timely file its Form 10-Q for Q2 2026, and has until July 20, 2026 to submit a compliance plan. The notification has no immediate effect on the company's stock listing but signals regulatory compl…